The company has agreed to acquire Verve Therapeutics for an upfront payment of approximately $1 billion. The total could increase significantly, however, if certain milestones are met. One of Verve's biggest gene therapies has already received the FDA's fast track designation.

Some infusion systems manufactured by Zyno Medical were released with unapproved software that could cause safety features to malfunction. Use of any device subject to the recall is to cease immediately. 

“Just as medicine has its own language, so does business," two surgeons explained in a new editorial. 

The Aventus Thrombectomy System was already cleared to treat blood clots in the peripheral arteries. This latest approval comes after positive results from an IDE study were published in JSCAI.

Even TAVR patients not treated using transfemoral access can typically go home the very next day. 

By identifying these structural changes prior to the onset of symptomatic neurodegeneration, providers may be able to initiate preventive therapies sooner.

The EARLY TAVR clinical trial made a significant impact, paving the way for the FDA to approve multiple transcatheter heart valves for the treatment of asymptomatic patients. However, one cardiologist who participated in the trial has some serious concerns with how its findings were presented to the public. 

The new name will be familiar to anyone who knows the history of Medtronic's diabetes business.